Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1649-1651.
doi: 10.21037/tlcr-23-237. Epub 2023 May 22.

ADAURA update: only the end of the beginning

Bharathi Muthusamy  1 , Nathan A Pennell  1
Affiliations
Editorial

ADAURA update: only the end of the beginning

Bharathi Muthusamy et al. Transl Lung Cancer Res. .
No abstract available

Keywords: ADAURA; Non-small cell lung cancer (NSCLC); adjuvant osimertinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-237/coif). NAP received consulting fees from Merck, Pfizer, Mirati, Eli Lilly, Genentech, Sanofi Genzyme, Novartis, Takeda, Bayer, Summitt Therapeutics, and Anheart for participating in the Advisory Board. The other author has no conflicts of interest to declare.

Comment on

References

    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. NSCLC Meta-analyses Collaborative Group ; Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77. 10.1016/S0140-6736(10)60059-1 - DOI - PMC - PubMed
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Enttiger D, Wood D, Aisner D, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2. 2023. Available online: https://www.nccn.org/ (Accessed March 16, 2023).
    1. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol 2023;41:1830-40. Erratum in: J Clin Oncol 2023. 10.1200/JCO.22.02186 - DOI - PMC - PubMed